Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 10/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056199 | 0.92 | ALPL (0.45) | ALPLTRPV4CNR2ACLYEPAS1 | |
| SCHEMBL5704864 | 0.86 | TRPV4 (0.62) | ALPLTRPV4CNR2EPAS1SLC22A12 | |
| SCHEMBL8075332 | 0.85 | ALPL (0.50) | ALPLCNR2ACLYEPAS1SLC22A12 | |
| Hydrochloric Acid SCHEMBL28145247 | 0.83 | ALPL (0.50) | ALPLCNR2ACLYGSTO1 | |
| SCHEMBL29580886 | 0.83 | SLC22A12 (0.39) | ALPLEPAS1SLC22A12GSTO1KDM4E | |
| SCHEMBL15220356 | 0.83 | SLC22A12 (0.39) | ALPLEPAS1SLC22A12GSTO1KDM4E | |
| SCHEMBL15211993 | 0.81 | GSTO1 (0.40) | ALPLTRPV4GSTO1ALDH1A1HPGD | |
| SCHEMBL4617905 | 0.81 | ALPL (0.48) | ALPLSLC22A12GSTO1 | |
| SCHEMBL6260261 | 0.81 | ALPL (0.56) | ALPLCNR2ACLYSLC22A12 | |
| SCHEMBL10498632 | 0.79 | TRPV4 (0.45) | TRPV4ACLYKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0064322-B1 | BENZENESULFONYL ISOCYANATES, ISOTHIOCYANATES, CHLORIDES, AND SULFONAMIDES HAVING A FLUORINATED SUBSTITUENT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-05-22 | — | — | EP | claimed |
| EP-0064322-A2 | Benzenesulfonyl isocyanates, isothiocyanates, chlorides, and sulfonamides having a fluorinated substituent | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-11-10 | — | — | EP | claimed |
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3319970-B1 | PYRIDO-OXAZINONE DERIVATIVES AS TNAP INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2817292-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford-Burnham Medical Research Institute (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013126608-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013126608-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-29 | — | — | WO | disclosed |
| US-4725304-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1988-02-16 | — | — | US | disclosed |
| EP-0173318-A1 | Fluoralkoxyphenylsulfonyl guanidines | BAYER AG (DE) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | ALPL 4747/4885TRPV4 3890/4885CNR2 3915/4885 |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885TRPV4 495/4885CNR2 2772/4885 |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | ALPL 7/4885TRPV4 245/4885CNR2 1369/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | ALPL 5/4885TRPV4 548/4885CNR2 1604/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | ALPL 7/4885TRPV4 245/4885CNR2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.